Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 29, 2004

View Archived Issues

Alteon updates progress

Introgen requests accelerated approval BLA for Advexin

Micromet and EvoGenix sign agreement for single-chain antibodies

MorphoSys and Centocor extend antibody agreement

Phase II AVAC study in childhood eczema fails to meet primary endpoint

Zadaxin triple combination therapy tested in new European phase III trial

Xyzal approved in Europe for persistent allergic rhinitis

Further phase I study evaluates PTC-124

P&G withdraws Intrinsa NDA with plans to submit new application

GSK terminates MIV-210 partnership

Japanese Council recommends approval of Crestor

IND approved for phase II trial of AVR-118 in advanced malignancies

Sustained anorectic effect of the CB1 receptor antagonist, AM-251, shown in rats

NitroMed submits BiDil NDA amendment

Not approvable letter for Cellegesic

Sankyo team isolates antidiabetic compound from a natural source

Daiichi researchers test novel compounds for the treatment of cancer

Scientists at Takeda prepare and test RFRP receptor antagonists

PPAR modulators disclosed in a patent

Protein tyrosine phosphatase-1B inhibitors for diabetes

Pegvisomant may be effective in the treatment of breast cancer

Phase III data on the efficacy of dexanabinol in severe traumatic brain injury

Novel agents to treat chronic myeloid leukemia

A phase III trial confirms the therapeutic benefits of RSD-1235 in AF

Promising effects reported for add-on Advexin therapy in locally advanced breast cancer

Update on the survival effects of add-on efaproxiral in breast cancer patients with brain metastases

First data on the use of permanent 103-palladium seed implants in breast cancer

Good efficacy and safety profile reported for tiagabine in GAD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...